Showing 3791-3800 of 5559 results for "".
- Promius Pharma Launches Promiseb Topical Cream 60 Gram Optionhttps://practicaldermatology.com/news/20141105-promius_pharma_launches_promiseb_topical_cream_60_gram_option/2459073/Promius Pharma LLC launched Promiseb Topical Cream in a new 60 gram box. This well-regarded non-steroidal cream for the treatment of seborrheic
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- Harvard Business Review Names Allergan's David E. I. Pyott a Top CEOhttps://practicaldermatology.com/news/20141015-harvard_business_review_names_allergans_david_e_i_pyott_a_top_ceo/2459084/David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, Inc., has been ranked the 4th best-performing CEO in the world by the Harvard Business Review (HBR). Mr. Pyott was selected for this honor out of a total o
- INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20141014-inc_research_signs_agreement_to_perform_fda_due_diligence_audit_of_regulatory_documents_for_provectus_biopharmaceuticals/2459085/Provectus Biopharmaceuticals, Inc. has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10. The audit will be conducted in two phases, both of which are expected to be
- New Data for Topical Nitric Oxide Nanoparticles: Evidence in Animal Model of EDhttps://practicaldermatology.com/news/20141014-new_data_for_topical_nitrous_oxide_nanoparticles_evidence_in_animal_model_of_ed/2459086/Topically applied nitric oxide-releasing nanoparticles (NO-NPs) induced spontaneous erections and increased basal ICP in an animal model of radical prostatectomy. According to findings published in The Journal o
- Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercializationhttps://practicaldermatology.com/news/20141008-coronado_biosciences_forms_subsidiary_to_acquire_and_license_dermatology_products_for_commercialization/2459090/Coronado Biosciences, Inc. has formed a wholly owned subsidiary called, Journey Medical Corporation (JMC) to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid respons
- Sirona Biochem: Obagi Medical Products Begins Manufacturing Scale-Up of Skin Lightening Agenthttps://practicaldermatology.com/news/20141008-sirona_biochem_obagi_medical_products_begins_manufacturing_scale-up_of_skin_lightening_agent/2459092/Sirona Biochem Corp. announced that its partner Obagi Medical Products Inc., a wholly-owned subsidiary of Valeant Pharmaceuticals International Inc., has started manufacturing scale-up of the skin lightening compound (TFC-849) originally developed by Sirona's scientists in Franc
- Galderma Initiates US Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/20141006-galderma_initiates_us_study_of_novel_muscle_relaxant_for_aesthetic_dermatology_and_cosmetic_surgery/2459095/Galderma has initiated a Phase II clinical trial of a novel muscle relaxant in the US. The Phase II clinical trial is a multicenter, dose-ranging study designed to evaluate the safety and effectiveness of Galderma's internally developed liquid form of botulinum toxin for the tre
- The ISDS Awards Scholarships to Young Doctors from Around the Worldhttps://practicaldermatology.com/news/20140917-the_isds_awards_scholarships_to_young_doctors_from_around_the_world/2459117/20 young doctors have been awarded generous scholarships from twenty leaders of the International Society for Dermatologic Surgery (ISDS) to attend an ISDS medical conference. This year, the scholarships were awarded to young doctors from Europe, Asia, Latin America (including Cuba), and
- Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase III Psoriasis Studieshttps://practicaldermatology.com/news/20140822-lillys_ixekizumab_superior_to_etanercept_and_placebo_in_phase_iii_psoriasis_studies/2459137/Eli Lilly and Company's ixekizumab was found to be statistically superior to etanercept and placebo on all skin clearance measures in pivotal, Phase III UNCOVER studies in moderate-to-severe plaque psoriasis. "These data are important for people suffer